In recent years, increased attention has focused on
the recognition and treatment of anxiety disorders.
These syndromes include generalized anxiety disorder,
social anxiety disorder, posttraumatic stress disorder,
panic disorder, obsessive compulsive disorder, and specific
phobias. The impact of anxiety disorders is enormous
in terms of loss of human societal contributions, financial
costs, and lost quality of life. A thorough understanding
of these syndromes involves a review of their possible
origin and etiology, including early childhood events
and possible genetic and neurobiological influences.
Theories as to the sources of anxiety disorders and
the neurochemical and neuroanatomical bases of anxiety
disorders will be discussed. The treatment of anxiety
disorders focuses on modulating underlying neurochemical
disturbances, either through psycho- or pharmacological
therapies. Combinations of psychotherapy and the use
of different drug classes and drug combinations, tailored
to specific anxiety disorders, will be reviewed, with
particular emphasis on new and emerging therapies.
Anxiety Disorders: Sources, Signs, and Solutions
is intended for physicians and pharmacists interested
in the recognition and treatment of anxiety disorders.
Enrollment in this activity is complimentary.
To understand the symptoms, identification, and treatment
of anxiety disorders
Upon completion of this activity, participants should
be able to:
- Review the incidence, impact, symptomatology, cause,
and treatment of anxiety disorders, including new
therapies
- Evaluate the possible impact of generalized anxiety
disorder on the patient and society and review potential
pharmacological treatments for this disorder
- Understand the potential childhood basis of anxiety
disorders, and discuss possible early interventions
- Discuss the somatic symptoms associated with anxiety
disorders and propose solutions for collaborative
management that involve both the primary care physician
and the psychiatrist
- Recognize the possible origins and treatments of social anxiety disorder
This activity has been planned and implemented in
accordance with the Essential Areas and Policies of
the Accreditation Council for Continuing Medical Education
through the joint sponsorship of The FCG Institute
for Continuing Education and IntraMed Educational
Group. The FCG Institute for Continuing Education
is accredited by the ACCME to provide continuing medical
education for physicians.
The American Medical Association has determined that
physicians not licensed in the US who participate
in this CME activity are eligible for AMA PRA category
1 credit.
The FCG Institute for Continuing Education designates
this educational activity for a maximum of 2.5 category
1 credits toward the AMA Physician’s Recognition Award.
Each physician should claim only those credits that
he/she actually spent in the activity.
 |
The FCG Institute for Continuing Education
is accredited by the American Council on Pharmaceutical
Education as a provider of continuing pharmaceutical
education. This program has been assigned the
Universal Program Number 086-999-03-028-H01 and
has been approved for 2.5 contact hours (0.25
CEUs).
|
To receive CME or CPE credit, you must view all the
online presentations, complete an evaluation, complete
and score 70% or higher on the post-test, and register
on this site. After you complete these steps, you
may print your certificate or statement of credit
online. That’s it—no need to wait for
your certificate to be mailed to you!
The release date of this activity was November 12, 2003,
and it will expire on November 12, 2004. This activity
can be completed in approximately 2.5 hours. This
program is based on an Industry-Supported Symposium
presented at the American Psychiatric Association
156th Annual Meeting. The APA was not involved in,
and received no commercial support for the development
of this product and does not award CME credit for
this program.
Disclosure Statement
It is the policy of The FCG Institute for Continuing
Education to ensure independence, balance, objectivity,
and scientific rigor and integrity in all its CE activities.
Faculty must disclose to the participants any significant
relationships with commercial companies whose products
or devices may be mentioned in faculty presentations,
or with the commercial supporter of this activity.
Disclosure information is for participant information.
It is not assumed that these relationships will have
a negative impact on the presentations. Faculty disclosures
can be found in Faculty Info.
Unlabeled or Investigational Use Statement
Faculty of this CE activity may include discussions
of products or devices that are not currently labeled
for use by the US Food and Drug Administration (FDA).
Faculty members have been asked to disclose to the
audience any reference to an unlabeled or investigational
use.
The FCG Institute for Continuing Education, the faculty,
and Forest Pharmaceuticals, Inc. do not endorse the
use of any product outside of the FDA-labeled indications.
Healthcare professionals should not utilize the procedures,
products, or diagnostic techniques discussed during
this activity without evaluation of their patients
for contraindications or dangers of use.
|
